193 related articles for article (PubMed ID: 36404640)
21. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
[TBL] [Abstract][Full Text] [Related]
22. Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters.
Díaz-Antón B; Madurga R; Zorita B; Wasniewski S; Moreno-Arciniegas A; López-Melgar B; Ramírez Merino N; Martín-Asenjo R; Barrio P; Amado Escañuela MG; Solís J; Parra Jiménez FJ; Ciruelos E; Castellano JM; Fernández-Friera L
ESC Heart Fail; 2022 Apr; 9(2):1127-1137. PubMed ID: 35106939
[TBL] [Abstract][Full Text] [Related]
23. Multi-parameter cardiac magnetic resonance imaging detects anthracycline-induced cardiotoxicity in rabbits model.
Hu Y; Ma P; Chen L; Liu J; Shang Y; Jian W
Heliyon; 2023 Nov; 9(11):e21845. PubMed ID: 38058655
[TBL] [Abstract][Full Text] [Related]
24. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Impact of Global Longitudinal Strain and NT-proBNP on Early Development of Cardiotoxicity in Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy.
Muckiene G; Vaitiekus D; Zaliaduonyte D; Zabiela V; Verseckaite-Costa R; Vaiciuliene D; Juozaityte E; Jurkevicius R
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241185
[No Abstract] [Full Text] [Related]
26. Diffuse Myocardial Fibrosis and Inflammation in Rheumatoid Arthritis: Insights From CMR T1 Mapping.
Ntusi NAB; Piechnik SK; Francis JM; Ferreira VM; Matthews PM; Robson MD; Wordsworth PB; Neubauer S; Karamitsos TD
JACC Cardiovasc Imaging; 2015 May; 8(5):526-536. PubMed ID: 25890584
[TBL] [Abstract][Full Text] [Related]
27. The diagnostic value of multiparameter cardiovascular magnetic resonance for early detection of light-chain amyloidosis from hypertrophic cardiomyopathy patients.
Yue X; Yang L; Wang R; Chan Q; Yang Y; Wu X; Ruan X; Zhang Z; Wei Y; Wang F
Front Cardiovasc Med; 2022; 9():1017097. PubMed ID: 36330005
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
Dodos F; Halbsguth T; Erdmann E; Hoppe UC
Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
[TBL] [Abstract][Full Text] [Related]
29. Aerobic Fitness Is Related to Myocardial Fibrosis Post-Anthracycline Therapy.
Kirkham AA; Paterson DI; Haykowsky MJ; Beaudry RI; Mackey JR; Pituskin E; Grenier JG; Thompson RB
Med Sci Sports Exerc; 2021 Feb; 53(2):267-274. PubMed ID: 32826630
[TBL] [Abstract][Full Text] [Related]
30. Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT.
Tahir E; Azar M; Shihada S; Seiffert K; Goy Y; Beitzen-Heineke A; Molwitz I; Muellerleile K; Stehning C; Schön G; Adam G; Petersen C; Müller V; Lund GK
Eur Radiol; 2022 Mar; 32(3):1853-1865. PubMed ID: 34536111
[TBL] [Abstract][Full Text] [Related]
31. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
32. Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial.
Heck SL; Gulati G; Hoffmann P; von Knobelsdorff-Brenkenhoff F; Storås TH; Ree AH; Gravdehaug B; Røsjø H; Steine K; Geisler J; Schulz-Menger J; Omland T
Eur Heart J Cardiovasc Imaging; 2018 May; 19(5):544-552. PubMed ID: 29106497
[TBL] [Abstract][Full Text] [Related]
33. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy.
Neilan TG; Coelho-Filho OR; Shah RV; Feng JH; Pena-Herrera D; Mandry D; Pierre-Mongeon F; Heydari B; Francis SA; Moslehi J; Kwong RY; Jerosch-Herold M
Am J Cardiol; 2013 Mar; 111(5):717-22. PubMed ID: 23228924
[TBL] [Abstract][Full Text] [Related]
34. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
35. Speckle tracking echocardiography predicts early subclinical anthracycline cardiotoxicity in patients with breast cancer.
Tang Q; Jiang Y; Xu Y; Xia H
J Clin Ultrasound; 2017 May; 45(4):222-230. PubMed ID: 27910996
[TBL] [Abstract][Full Text] [Related]
36. Abnormalities in 3-Dimensional Left Ventricular Mechanics With Anthracycline Chemotherapy Are Associated With Systolic and Diastolic Dysfunction.
Zhang KW; Finkelman BS; Gulati G; Narayan HK; Upshaw J; Narayan V; Plappert T; Englefield V; Smith AM; Zhang C; Hundley WG; Ky B
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1059-1068. PubMed ID: 29550306
[TBL] [Abstract][Full Text] [Related]
37. A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis.
Chamling B; Bietenbeck M; Drakos S; Korthals D; Vehof V; Stalling P; Meier C; Yilmaz A
Sci Rep; 2022 Dec; 12(1):21755. PubMed ID: 36526658
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular magnetic resonance characterization of myocardial tissue injury in a miniature swine model of cancer therapy-related cardiovascular toxicity.
Nakata K; Kucukseymen S; Cai X; Yankama T; Rodriguez J; Sai E; Pierce P; Ngo L; Nakamori S; Tung N; Manning WJ; Nezafat R
J Cardiovasc Magn Reson; 2024 Mar; 26(1):101033. PubMed ID: 38460840
[TBL] [Abstract][Full Text] [Related]
39. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
[TBL] [Abstract][Full Text] [Related]
40. Long term cardiovascular magnetic resonance phenotyping of anthracycline cardiomyopathy.
Harries I; Biglino G; Baritussio A; De Garate E; Dastidar A; Plana JC; Bucciarelli-Ducci C
Int J Cardiol; 2019 Oct; 292():248-252. PubMed ID: 31006597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
